ProCE Banner Activity

Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From France

Podcast Episodes
Listen to Alain Ravaud, MD, PhD, and Marine Gross-Goupil, MD, PhD, discuss in French the latest clinical data on immune checkpoint inhibitors for advanced urothelial cancer.

Released: November 19, 2020

Expiration: November 18, 2021

No longer available for credit.

Share

Faculty

Marine Gross-Goupil

Marine Gross-Goupil, MD, PhD

Medical Oncologist
Department of Medical Oncology
University Hospital
Bordeaux, France

Alain Ravaud

Alain Ravaud, MD, PhD

Professor of Medical Oncology
Bordeaux University
Head of Medical Oncology
Department of Medical Oncology
Bordeaux University Hospital,
Bordeaux, France

Supporters

Supported by an educational grant from

Pfizer and EMD Serono

Faculty Disclosure

Primary Author

Marine Gross-Goupil, MD, PhD

Medical Oncologist
Department of Medical Oncology
University Hospital
Bordeaux, France

Marine Gross-Goupil, MD, PhD, has disclosed that she has received funds for research support from Janssen and consulting fees from Astellas, Merck, Pfizer, and Roche.

Alain Ravaud, MD, PhD

Professor of Medical Oncology
Bordeaux University
Head of Medical Oncology
Department of Medical Oncology
Bordeaux University Hospital,
Bordeaux, France

Alain Ravaud, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Ipsen, Merck, MSD, Novartis, Pfizer, and Roche.